Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020538 (
hypertension
)
170,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fibronectin glomerulopathy (
GFND
) is a newly recognized autosomal dominant disease of the kidney that results in albuminuria, microscopic hematuria,
hypertension
, renal tubular acidosis type IV, and end-stage renal disease in the 2d to 6th decade of life. The disease is characterized histologically by massive deposits of fibronectin (Fn) present in the subendothelial spaces of renal glomerular capillaries. The cause of human
GFND
is unknown. In order to localize a candidate gene for
GFND
, we performed linkage analysis of a large, 193-member pedigree containing 13 affected individuals. Since we had previously excluded the genes for Fn and uteroglobin as candidate genes for
GFND
, a total-genome search for linkage was performed. Examination of 306 microsatellite markers resulted in a maximum two-point LOD score of 4.17 at a recombination fraction of. 00 for marker D1S249, and a maximum multipoint LOD score of 4.41 for neighboring marker D1S2782. By detection of recombination events, a critical genetic interval of 4.1 cM was identified, which was flanked by markers D1S2872 and D1S2891. These findings confirm that
GFND
is a distinct disease entity among the fibrillary glomerulopathies. Gene identification will provide insights into the molecular interactions of Fn in
GFND
, as well as in genetically unaltered conditions.
...
PMID:The gene for human fibronectin glomerulopathy maps to 1q32, in the region of the regulation of complement activation gene cluster. 983 25
Glomerulopathy with fibronectin (FN) deposits (
GFND
) is an autosomal dominant disease with age-related penetrance, characterized by proteinuria, microscopic hematuria,
hypertension
, and massive glomerular deposits of FN that lead to end-stage renal failure. The genetic abnormality underlying
GFND
was still unknown. We hypothesized that mutations in FN1, which encodes FN, were the cause of
GFND
. In a large Italian pedigree with eight affected subjects, we found linkage with
GFND
at the FN1 locus at 2q32. We sequenced the FN1 in 15 unrelated pedigrees and found three heterozygous missense mutations, the W1925R, L1974R, and Y973C, that cosegregated with the disease in six pedigrees. The mutations affected two domains of FN (Hep-II domain for the W1925R and the L1974R, and Hep-III domain for the Y973C) that play key roles in FN-cell interaction and in FN fibrillogenesis. Mutant recombinant Hep-II fragments were expressed, and functional studies revealed a lower binding to heparin and to endothelial cells and podocytes compared with wild-type Hep-II and an impaired capability to induce endothelial cell spreading and cytoskeletal reorganization. Overall dominant mutations in FN1 accounted for 40% of cases of
GFND
in our study group. These findings may help understanding the pathogenesis of proteinuria and glomerular FN deposits in
GFND
and possibly in more common renal diseases such as diabetic nephropathy, IgA nephropathy, and lupus nephritis. To our knowledge no FN1 mutation causing a human disease was previously reported.
...
PMID:Mutations in FN1 cause glomerulopathy with fibronectin deposits. 1826 55